Xuan Y T, Guo Y, Han H, Zhu Y, Bolli R
Experimental Research Laboratory, Division of Cardiology, University of Louisville and the Jewish Hospital Heart and Lung Institute, Louisville, KY 40292, USA.
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9050-5. doi: 10.1073/pnas.161283798.
The goal of this study was to determine the role of the Janus tyrosine kinase (JAK)-signal transducers and activators of transcription (STAT) pathway in the late phase of ischemic preconditioning (PC). A total of 230 mice were used. At 5 min after ischemic PC (induced with six cycles of 4-min coronary occlusion/4-min reperfusion), immunoprecipitation with anti-phosphotyrosine (anti-pTyr) antibodies followed by immunoblotting with anti-JAK antibodies revealed increased tyrosine phosphorylation of JAK1 (+257 +/- 53%) and JAK2 (+238 +/- 35%), indicating rapid activation of these two kinases. Similar results were obtained by immunoblotting with anti-pTyr-JAK1 and anti-pTyr-JAK2 antibodies. Western analysis with anti-pTyr-STAT antibodies demonstrated a marked increase in nuclear pTyr-STAT1 (+301 +/- 61%) and pTyr-STAT3 (+253 +/- 60%) 30 min after ischemic PC, which was associated with redistribution of STAT1 and STAT3 from the cytosolic to the nuclear fraction and with an increase in STAT1 and STAT3 gamma-IFN activation site DNA-binding activity (+606 +/- 64%), indicating activation of STAT1 and STAT3. No nuclear translocation or tyrosine phosphorylation of STAT2, STAT4, STAT5A, STAT5B, or STAT6 was observed. Pretreatment with the JAK inhibitor AG-490 20 min before the six occlusion/reperfusion cycles blocked the enhanced tyrosine phosphorylation of JAK1 and JAK2 and the increased tyrosine phosphorylation, nuclear translocation, and enhanced DNA-binding activity of STAT1 and STAT3. The same dose of AG-490 abrogated the protection against myocardial infarction and the concomitant up-regulation of inducible NO synthase (iNOS) protein and activity observed 24 h after ischemic PC. Taken together, these results demonstrate that ischemic PC induces isoform-selective activation of JAK1, JAK2, STAT1, and STAT3, and that ablation of this response impedes the up-regulation of iNOS and the concurrent acquisition of ischemic tolerance. This study demonstrates that the JAK-STAT pathway plays an essential role in the development of late PC. The results reveal a signaling mechanism that underlies the transcriptional up-regulation of the cardiac iNOS gene and the adaptation of the heart to ischemic stress.
本研究的目的是确定Janus酪氨酸激酶(JAK)-信号转导子和转录激活子(STAT)通路在缺血预处理(PC)后期的作用。总共使用了230只小鼠。在缺血性PC(通过6个周期的4分钟冠状动脉闭塞/4分钟再灌注诱导)后5分钟,用抗磷酸酪氨酸(抗-pTyr)抗体进行免疫沉淀,随后用抗JAK抗体进行免疫印迹,结果显示JAK1(+257±53%)和JAK2(+238±35%)的酪氨酸磷酸化增加,表明这两种激酶被快速激活。用抗-pTyr-JAK1和抗-pTyr-JAK2抗体进行免疫印迹也得到了类似结果。用抗-pTyr-STAT抗体进行Western分析显示,缺血性PC后30分钟,核内pTyr-STAT1(+301±61%)和pTyr-STAT3(+253±60%)显著增加,这与STAT1和STAT3从胞质向核部分的重新分布以及STAT1和STAT3γ-干扰素激活位点DNA结合活性增加(+606±64%)相关,表明STAT1和STAT3被激活。未观察到STAT2、STAT4、STAT5A、STAT5B或STAT6的核转位或酪氨酸磷酸化。在6个闭塞/再灌注周期前20分钟用JAK抑制剂AG-490预处理,可阻断JAK1和JAK2增强的酪氨酸磷酸化以及STAT1和STAT3增加的酪氨酸磷酸化、核转位和增强DNA结合活性。相同剂量的AG-490消除了缺血性PC后24小时观察到的对心肌梗死的保护作用以及诱导型一氧化氮合酶(iNOS)蛋白和活性的同时上调。综上所述,这些结果表明缺血性PC诱导JAK1、JAK2、STAT1和STAT3的亚型选择性激活,并且消除这种反应会阻碍iNOS的上调和同时获得的缺血耐受性。本研究表明JAK-STAT通路在晚期PC的发展中起重要作用。结果揭示了一种信号传导机制,该机制是心脏iNOS基因转录上调以及心脏对缺血应激适应的基础。